Compare GCT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | ATAI |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2022 | 2021 |
| Metric | GCT | ATAI |
|---|---|---|
| Price | $39.42 | $4.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $24.00 | $14.33 |
| AVG Volume (30 Days) | 481.6K | ★ 3.2M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.32 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $1,222,932,000.00 | $3,018,000.00 |
| Revenue This Year | $9.56 | $943.18 |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $11.96 | ★ N/A |
| Revenue Growth | 10.17 | ★ 811.78 |
| 52 Week Low | $11.17 | $1.15 |
| 52 Week High | $43.85 | $6.75 |
| Indicator | GCT | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 46.02 |
| Support Level | $38.89 | $3.90 |
| Resistance Level | $41.50 | $4.72 |
| Average True Range (ATR) | 1.74 | 0.24 |
| MACD | -0.41 | 0.01 |
| Stochastic Oscillator | 28.85 | 23.21 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.